Cort
Phoenix Rising Founder
- Messages
- 7,392
The Human Isolate Question-The WPI appears to propose that their use of a human isolate of XMRV allowed them to find an XMRV-like family of viruses containing VP62 strains, p variants of the virus (Lo et. als pMLVs) and other strains and that Dr. Singhs use of an XMRV clone developed from the VP62 strain lead her to miss those strains and that is one reason that she didnt find anything.
(Note though that the WPI did say that the patients they directed to Dr. Singh tested positive for antibodies to the VP62 strain - which, given the increased sensitivity of Dr. Singhs tests she should have been more effective at picking up.The WPIs argument regarding using a human isolate possibly explain reduced results but its hard to understand how it could explain zero results. The data from the original study indicated that tests using VP62 were adequate to pick the type of XMRV found in that study. ).
(Note though that the WPI did say that the patients they directed to Dr. Singh tested positive for antibodies to the VP62 strain - which, given the increased sensitivity of Dr. Singhs tests she should have been more effective at picking up.The WPIs argument regarding using a human isolate possibly explain reduced results but its hard to understand how it could explain zero results. The data from the original study indicated that tests using VP62 were adequate to pick the type of XMRV found in that study. ).
I asked Dr. Singh if she felt her use of the VP62 clone impaired her ability to find all the XMRV or XMRV-like sequences that were present? She replied that retroviral tests should be able to easily pick up the amount of variation that has been published thus far.
VP62 is a human isolate of XMRV - it was isolated from a patient with prostate cancer. There are hardly any differences between VP62 and XMRV isolates from the Mikovits lab - a total of 8 to 32 bases among 8000 bases. That is a difference of only 0.1 to 0.4% - which for retroviruses is not much variation at all, given that they utilize an enzyme that cannot proof-read for their replication. Using any one of the 6 published isolates of XMRV should lead to outcomes that are not significantly different.
Exact Replication? Dr. Singh reported in her paper that she replicated the methods of the Lombardi paper but there were differences. I asked if she was could be getting different results because of small differences in preparation and testing?
She stated
We used a total of 9-12 assays on each sample to look for XMRV. Some were new assays that we developed - and these assays are far more sensitive than any of the assays where sensitivity data is shown. Others were a replication of assays performed in Lombardi et al or Lo et al. The viral culture was done exactly as explained by Dr. Ruscetti.
And then explained one difference that she felt was missing in both the Lombardi and Lo studies which meant the studies were prone to contamination; ie there was one part of those studies that she felt compelled not to replicate.
The nested PCR was done as described in Lo et al, with one small modification. We used the dUTP-UNG system to prevent contamination of our lab with PCR products.
Since nested PCRs involve opening of tubes containing a PCR product, the danger of this product contaminating other equipment, reagents and samples in the lab is very real. Once contamination has occurred, it is very difficult to get rid of it. Any reputable lab that uses PCR as a test on clinical samples, uses dUTP-UNG. It has been shown to not affect the PCR itself, and to provide a very real safeguard against contamination.
I do not know why Lo et al or Lombardi et al used a process prone to contamination like the nested PCR, and then did not use the dUTP-UNG system (you'll have to ask them). But I could not risk contaminating my lab with PCR amplicons - then every subsequent test we did would be suspect.